Objective-Common genetic variants in a 58-kb region of chromosome 9p21, near the CDKN2A/CDKN2B tumor suppressor locus, are strongly associated with coronary artery disease. However, the underlying mechanism of action remains unknown. Methods and Results-We previously reported a congenic mouse model harboring an atherosclerosis susceptibility locus and the region of homology with the human 9p21 locus. Microarray and transcript-specific expression analyses showed markedly decreased Cdkn2a expression, including both p16 INK4a and p19 ARF , but not Cdkn2b (p15 INK4b ), in macrophages derived from congenic mice compared with controls. Atherosclerosis studies in subcongenic strains revealed genetic complexity and narrowed 1 locus to a small interval including Cdkn2a/b. Bone marrow (BM) transplantation studies implicated myeloid lineage cells as the culprit cell type, rather than resident vascular cells. To directly test the role of BM-derived Cdkn2a transcripts in atherogenesis and inflammatory cell proliferation, we performed a transplantation study using Cdkn2a ϩ/Ϫ cells in the Ldlr Ϫ/Ϫ mouse model. Cdkn2a-deficient BM recipients exhibited accelerated atherosclerosis, increased Ly6C hi proinflammatory monocytes, and increased monocyte/macrophage proliferation compared with controls. Conclusion-These data provide a plausible mechanism for accelerated atherogenesis in susceptible congenic mice, involving decreased expression of Cdkn2a and increased proliferation of monocyte/macrophages, with possible relevance to the 9p21 human locus. (Arterioscler Thromb Vasc Biol. 2011;31:2483-2492.)
A therosclerotic vascular disease (ASVD) is the leading cause of death in Western societies. Complications of the disease are usually caused by rupture or erosion of an unstable atherosclerotic plaque, resulting in thrombus formation and arterial occlusion. 1 The complex etiology involves both genetic and environmental factors. Although genetic factors underlying traditional risk factors are well known, 2 new data emerging from genome-wide association studies are revealing novel loci mediating disease susceptibility independent of traditional factors. 3 In particular, a risk locus on chromosome (chr) 9p21.3 is strongly associated with ASVD (including myocardial infarction, stroke, and aortic aneurysm) but independent of plasma cholesterol levels and hypertension. 4 -6 Although the association with ASVD is robust and has been widely replicated in different ethnic groups, the underlying pathogenic mechanism remains unknown.
The association at 9p21 appears to be the most robust common (minor allele frequency Ͼ10%) genetic determinant for ASVD in the human genome. The single-nucleotide poly-morphisms most strongly associated with disease risk map to a 58-kb region containing a long, noncoding RNA (ANRIL) and lying Ϸ100 kb centromeric to the CDKN2A/B locus encoding inhibitors of cellular proliferation. Multiple ANRIL splice variants exist, complicating genetic association studies. 7 Decreased expression of the tumor suppressors p16 INK4a , p19 ARF , and p15 INK4b has been observed among carriers of the ASVD risk allele in some studies 8, 9 but not others. 10 -12 Targeted deletion of the homologous region in mice resulted in markedly decreased expression of Cdkn2a/b transcripts and increased proliferation of vascular smooth muscle cells (vSMCs) in vitro. However, no effect on atherosclerosis was observed in the Western diet-fed wild-type background mice, a highly atheroresistant model. 13 Thus, the potential role of these transcripts and the pathogenic mechanism leading to increased atherosclerotic risk at the 9p21 locus remains unclear.
We have used a murine genetic approach to map atherosclerosis susceptibility loci, including a locus on mouse chr 4 that was confirmed in a congenic strain. 14, 15 The effect on disease susceptibility was independent of plasma cholesterol levels, body weight, and plasma glucose levels. 15 We now report refined genetic mapping indicating that the introgressed interval contains at least 2 loci, 1 overlapping the Athsq1 quantitative trait locus and 1 covering the region of homology with the human 9p21 ASVD locus. Gene expression studies revealed decreased mRNA levels of p16 INK4a and p19 ARF , but not p15 INKb4 , in macrophages derived from susceptible congenic mice. Mechanistically, we investigated the hypothesis that increased proliferation of macrophages (or mixed populations of monocyte/macrophages) due to reduced expression of Cdkn2a cell proliferation inhibitor transcripts in myeloid lineage cells might be responsible, at least in part, for the accelerated atherosclerosis phenotype.
Methods
An expanded Methods section is available in the Supplemental Methods, available online at http://atvb.ahajournals.org. B6.MOLF-Athsq1 congenic mice were bred as described. 15 Cdkn2a Ϫ/Ϫ mice 16 backcrossed into B6 17 were kindly provided by Dr Sean Morrison (University of Michigan). Gene expression profiling or real-time polymerase chain reaction was carried out using peritoneal or splenic monocyte/macrophages. Raw profiling data are available in the National Center for Biotechnology Information GEO database (GSE 24342). Atherosclerotic lesions were quantified using morphometric analysis as described. 14, 15 Bone marrow (BM) transplantation experiments were performed as described. 18 Monocyte subsets were analyzed by standard flow cytometry analysis. 19 Two-factor ANOVA and t tests were performed using Statview 5.0 (Abacus Concepts, Inc). The threshold for significance was Pϭ0.05. Data shown are meanϮSEM.
Results

Genetic Complexity of an Atherosclerosis Susceptibility Locus Containing Athsq1, as Well as a 5.4-to 9-Mb Interval Containing Cdkn2a/b
A series of subcongenic strains was generated to narrow a previously reported 15 54-Mb interval on chr 4 harboring an atherosclerosis susceptibility gene(s). Mice were bred to homozygosity, fed 9-week Western-type diet (WTD), and analyzed for atherosclerotic lesion development. Mice carrying a 17-or 11-Mb proximal subinterval but not the 4-Mb proximal tip exhibited approximately 2-fold greater mean lesion area than noncongenic controls (PϽ0.0001) ( Figure  1A and 1B). The effect was observed in both males and females. The negative lesion phenotype of the 4-Mb subcongenic was confirmed in a second cohort (Supplemental Figure  I) . These data narrow the proximal interval to a 5.4-to 9-Mb region containing 8 to 21 known protein coding genes, including Cdkn2a/b ( Figure 1C ). Of note, this locus did not segregate with versican accumulation (data not shown), a phenotype originally observed in the full congenic strain. 15 An additional distal locus was identified in a subcongenic strain carrying a nonoverlapping donor interval (Supplemental Figure IB and IC). The distal locus overlaps the linkage peak from the original Athsq1 mapping cross, but detailed mapping and phenotypic assessment have not been carried out. Together, the data indicate genetic complexity of the full 54-Mb interval, with refined mapping of the proximal locus leading to identification of a critical region containing 8 to 21 genes.
Having previously demonstrated a role for BM-derived cells in determining the proatherosclerotic phenotype of Athsq1 congenics, 15 we now performed a reverse BM transplantation to determine whether vSMCs or endothelial cells contributed to the phenotype as well. B6-Ldlr Ϫ/Ϫ BM was injected into lethally irradiated 17-Mb subcongenics and noncongenic controls. Following repopulation of the BM, mice were fed 11-week WTD and analyzed for atherosclerotic lesion development. No difference in mean lesion area was observed between the groups (Supplemental Figure II) . Similar results were obtained for males and females. Importantly, these data indicate that resident cells of the vessel wall are not involved in the accelerated atherosclerosis phenotype associated with the proximal 17-Mb locus. Thus, we focused further mechanistic studies of this strain in BM-derived monocyte/macrophages.
Microarray and Transcript-Specific Gene Expression Analyses Reveal Decreased Macrophage Expression of p16 INK4a and p19 ARF , but Not p15 INK4b , in Athsq1 Congenic Mice
As an independent approach to narrow the list of candidate genes (Ͼ600 genes in the full 54-Mb congenic interval and Ϸ160 genes in the 17-Mb interval), we performed gene expression analysis using microarrays. Elicited peritoneal macrophages derived from full (54-Mb) congenics and noncongenic controls were collected after 6-week WTD feeding. Differentially expressed genes were defined as exhibiting Ն20% difference in expression level, with a significance threshold corrected for multiple testing. 20 Three to 6 of the differentially expressed transcripts reside within the narrowed 5.4-to 9-Mb proximal interval and could be considered causal candidate genes (Table) . Strikingly, the most significant difference was a Ϸ6-fold decrease in Cdkn2a levels in congenic compared with control macrophages. Cdkn2a encodes 2 transcripts involved in cell proliferation regulation: p16 INK4a and p19 ARF . 21 The transcripts use different promoters and alternative reading frames, resulting in proteins with no amino acid homology. 22 Because of the Cdkn2a exonic structure, the microarray could not discern p16 INK4a versus p19 ARF transcripts. Transcript-specific real-time polymerase chain reaction confirmed the results in the 17-Mb subcongenic strain and showed reduced expression of both p16 INK4a and p19 ARF , but not the adjacent p15 INK4b transcript, in macrophages from the atherosclerosis-prone 54-and 17-Mb congenics compared with noncongenic controls (Figure 2A) . Similar results were observed for both transcripts in resident peritoneal macrophages, and for p16 INK4a in splenic monocyte/macrophages, from 54-and 17-Mb congenic mice compared with controls ( Figure 2B and 2C). Of note, gene expression in peripheral blood monocytes was low (with Ct values Ͼ38), and we could not reliably detect a difference between congenics and controls. Thus, an atherosclerosisprone murine strain exhibits decreased expression of the p16 INK4a and p19 ARF tumor suppressor genes in macrophages and mixed monocyte/macrophage populations.
BM-Specific Cdkn2a Deficiency Results in Accelerated Atherosclerosis, Increased Ly6C hi Monocytes, and Increased 5-Bromo-2-Deoxyuridine Incorporation Into Monocytes and Macrophages
To directly test the hypothesis that decreased Cdkn2a expression in BM-derived cells is proatherogenic, we performed a BM transplantation study using a previously described Cdkn2a-deficient mouse. The targeted mutation replaces exons 2 and 3 with a neo cassette, knocking out both p16 INK4a and p19 ARF expression, 16 and has been crossed into a uniform B6 background. 17 In an effort to simulate the modest reduction of p16 INK4a and p19 ARF expression observed in congenics compared with controls, we used donor B6-Ldlr ϩ/Ϫ mice heterozygous for the Cdkn2a null allele. B6-Ldlr Ϫ/Ϫ recipients were injected with B6-Ldlr ϩ/Ϫ or B6-Ldlr ϩ/Ϫ , Cdkn2a ϩ/Ϫ BM and fed 10-week WTD following repopulation of the BM. No differences were observed in body weight, plasma total cholesterol, high-density lipoprotein, or triglycerides (Supplemental Table I ). Resident peritoneal macrophages exhibited a 2.5-fold decrease in expression of p16 INK4a but not p19 ARF or p18 INK4c (another INK4-class gene encoded by a distant region of mouse chr 4) in B6-Ldlr ϩ/Ϫ , Cdkn2a ϩ/Ϫ recipients compared with controls ( Figure 3A) . Similarly, splenic CD11b ϩ monocyte/macrophages exhibited Ϸ4-fold decreases in both p16 INK4a and p19 ARF but not p18 INK4c (Figure 3B ). Importantly, mean atherosclerotic lesion area was increased in B6-Ldlr ϩ/Ϫ , Cdkn2a ϩ/Ϫ recipients compared with controls (Pϭ0.04, 2-factor ANOVA) ( Figure 3C) , with nonsignificant singlesex increases of 34% and 17% for males and females, respectively. Thus, heterozygous BM-specific deficiency of Cdkn2a is sufficient to confer a modestly accelerated atherosclerosis phenotype in mice.
To test potential atherogenic mechanisms consistent with decreased p16 INK4a or p19 ARF expression in monocyte/macrophages, we assessed apoptosis and measures of monocytosis in the BM transplanted mice. Terminal deoxynucleotidyl transferase dUTP nick-end labeling staining of atherosclerotic lesions revealed few positive cells and no difference between B6-Ldlr ϩ/Ϫ , Cdkn2a ϩ/Ϫ recipients and controls (data not shown). No differences were observed in circulating white blood cell counts or total monocytes in blood derived from B6-Ldlr ϩ/Ϫ , Cdkn2a ϩ/Ϫ recipients compared with controls (data not shown). However, flow cytometry analysis of blood monocytes revealed increased Ly6C hi monocytes after chow (0-week time point) and WTD feeding ( Figure 4A and 4B). Increased percentages of Ly6C hi and decreased percentages of Ly6C lo subsets ( Figure 4B ) resulted in a significant increase in the ratio of Ly6C hi :Ly6C lo monocytes in the circulation of B6-Ldlr ϩ/Ϫ , Cdkn2a ϩ/Ϫ recipients compared with controls (Supplemental Figure IIIA) . Note that the 0and 2-week time points are prelesional, indicating that increased Ly6C hi monocytes are not secondary to accelerated atherosclerosis. 15 To test for a direct effect of heterozygous Cdkn2a deficiency on monocyte proliferation, we injected mice with 5-bromo-2Ј-deoxyuridine (BrdU) before euthanization at the 10-week time point. B6-Ldlr ϩ/Ϫ , Cdkn2a ϩ/Ϫ recipients exhibited an increased percentage of BrdU ϩ monocytes compared with controls, indicating increased monocyte proliferation ( Figure 4C and 4D) . Moreover, the increase in BrdU incorporation occurs mainly in the Ly6C hi subset ( Figure 4C , left panel).
To test for an effect of BM-derived Cdkn2a deficiency on tissue macrophage proliferation, we assayed elicited peritoneal macrophages by flow cytometry following intraperitoneal BrdU injection. Although there was no difference in the total number of CD45 ϩ CD115 ϩ F4/80 ϩ macrophages ( Figure 5A ), there was a significant increase in the percentage of BrdU ϩ macrophages from B6-Ldlr Ϫ/Ϫ , Cdkn2a ϩ/Ϫ mice compared with B6-Ldlr Ϫ/Ϫ controls (PϽ0.04) ( Figure 5B and 5C ). We also tested for increased BrdU incorporation within lesions of a small cohort of B6-Ldlr Ϫ/Ϫ , Cdkn2a ϩ/Ϫ mice compared with controls using immunohistochemistry. Although ample numbers of cells (meanϭ42-47 cells) stained positively following a 7-day pulse, the within-group variation was high, and power calculations indicated that we would need to study 50 mice/group to have an 80% chance of detecting a significant difference (PϽ0.05) comparable in magnitude to the difference in lesion area (ie, Ϸ30%).
Together, these data provide direct evidence for a suppressive effect of BM-derived p16 INK4a or p19 ARF expression on inflammatory monocyte/macrophage proliferation.
Discussion
Before the identification of 9p21 as a risk locus for human ASVD, we used a murine genetic approach to identify the homologous region of mouse chr 4 as a modifier of athero- Fold change is listed for all transcripts encoded within the 5.4-to 9-Mb interval and exhibiting a Ն20% difference in expression level in peritoneal macrophages derived from Athsq1 54-Mb full congenic or noncongenic (b/b) mice fed 6-wk Western-type diet. nϭ10 mice/group. Note that Ptplad2 is listed twice (ϩ1.24-fold and Ϫ1.30-fold changes), with known splice variants exhibiting different expression patterns. sclerosis susceptibility. In the current study, we provided refined genetic mapping and transcriptional evidence that Cdkn2a mediates at least some of the altered atherosclerosis susceptibility of this region through altered expression in macrophages. In support of this model, heterozygous deficiency of Cdkn2a transcripts in BM-derived cells was sufficient to confer accelerated atherogenesis in the B6-Ldlr Ϫ/Ϫ background. The moderate (Ϸ2-4-fold) reduction in p16 INK4a and p19 ARF expression associated with increased atherosclerosis in these murine models is consistent with the reduction of p16 INK4a and p19 ARF expression in T cells of carriers of the 9p21 risk allele. 8 Moreover, our study shows for the first time that the underlying pathogenic mechanism may involve increased proliferation/expansion of the Ly6C hi inflammatory monocyte population in the circulation, as well as increased proliferation of tissue macrophages. This provides a plausible mechanism to account, in part, for accelerated atherogenesis in the chr 4 congenic mouse, with possible relevance to the mechanism of increased atherogenesis in humans bearing the 9p21 risk allele.
Consistent with our BM transplantation study, whole-body deletion of p19 ARF was recently shown to be proatherosclerotic in the B6-Apoe Ϫ/Ϫ background. 23 The mechanism of action suggested in the Apoe Ϫ/Ϫ model was decreased apoptosis, although the culprit cell type was not identified. We did not observe differences in plaque apoptosis in either the Athsq1 congenic model or mice carrying BM deficiency of Cdkn2a compared with the respective controls. The discrepancy between the 2 studies could be due to different experimental designs (BM versus whole-body deficiency), different targeted alleles (p16 INK4a /p19 ARF versus p19 ARF alone), different mouse models (Ldlr Ϫ/Ϫ versus Apoe Ϫ/Ϫ ), or a nontarget effect of a carrier gene in 1 of the mutant models. However, although decreased apoptosis may accelerate early lesion formation, increased apoptosis likely contributes to lesion progression to advanced plaques with clinically significant consequences, 24 such as myocardial infarction associated with 9p21.
Chr 4 mouse deletion mutants with decreased expression of all 3 Cdkn2a/b transcripts exhibited increased proliferation of vSMCs. 25 However, vSMC proliferation does not readily explain the human atherothrombotic phenotype because it generally leads to cap thickening and plaque stabilization. 26 The results of a reverse BM transplantation experiment reported herein were inconsistent with a role for vSMCs in the atherosclerosis phenotype of Athsq1 17-Mb subcongenic mice (Supplemental Figure II) . In line with this, Folkersen et al 27 failed to demonstrate an association between vascular gene expression of CDKN2A/B and 9p21 risk genotype.
Evidence for an association between elevated white blood cell counts and ASVD risk has been documented in more than a dozen prospective epidemiological studies. 28 There is also substantial evidence in animal models for a causal relationship between monocytosis and atherogene-sis. 29 -32 In mouse models of diet-induced atherosclerosis, the subset of Ly6C hi -expressing monocytes expands with hypercholesterolemia and selectively enters sites of inflammation, including atherosclerotic lesions, compared with the Ly6C lo subset. 33, 34 In addition, single gene mutations resulting in reduced blood monocytes also reduced atherosclerosis, independently of plasma cholesterol levels. [35] [36] [37] [38] Although the relationship between monocytosis and atherosclerosis has been well documented, detailed mechanisms responsible for monocytosis are lacking. Consistent with a recent finding, 19 our study suggests that the control of myeloid cell proliferation during hypercholesterolemia is an important factor determining magnitude of leukocytosis and the atherogenic response.
A variety of mechanisms for the involvement of CDKN2A/B, ANRIL, or both in the 9p21 ASVD locus have been proposed. Regulation of CDKN2A/B gene expression has been suggested to occur via a cis or trans mechanism(s) involving either the structurally overlapping ANRIL 9, 39 or other regulatory motifs residing within the 58-kb risk locus. 11, 40 It is also possible that ANRIL may mediate effects at 9p21 without involvement of CDKN2A/B, through regulation of gene expression at an unlinked locus. 41 The mouse genome does not contain a contiguous sequence with homology to ANRIL. However, markedly decreased expression of Cdkn2a/b transcripts in the 70-kb deletion mutant suggests the existence of a cis-acting enhancer. 13 In our Athsq1 congenic mouse, there is a loss of coordinate regulation with decreased expression of Cdkn2a (p16 INK4a and p19 ARF ) transcripts but not Cdkn2b (p15 INK4b ). Thus, in our model, the causal variant is likely to be cis-acting and specific to the Cdkn2a locus.
The 9p21 locus has been associated with multiple vascular phenotypes. These include myocardial infarction, 5 abdominal aortic and intracranial aneurysms, 42 is-chemic stroke, 43, 44 and peripheral artery disease. 45 Interestingly, monocyte/macrophage recruitment is an important process in cerebral aneurysm formation, and Ccl2 deficiency has been shown to inhibit macrophage accumulation in aneurysmal walls and significantly decrease aneurysm formation in an experimentally induced mouse model. 46 In another study, increased immunostaining of CD68 antigen was observed in intracranial aneurysms compared with control tissue. 47 In ischemic stroke, macrophage accumulation has been associated with severity of brain injury. 48 Thus, alterations in monocyte/macrophage proliferation could potentially provide a common underlying mechanism for vascular phenotypes associated with the 9p21 locus. 
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